Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.

Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS, Melcher AA.

Clin Cancer Res. 2010 Jun 1;16(11):3067-77. doi: 10.1158/1078-0432.CCR-10-0054. Epub 2010 May 18.

2.

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.

Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, Selby P, Vile R, Harrington KJ, Melcher AA.

Gene Ther. 2008 Sep;15(18):1257-70. doi: 10.1038/gt.2008.58. Epub 2008 Apr 10.

3.

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ.

Gene Ther. 2008 Jun;15(12):911-20. doi: 10.1038/gt.2008.21. Epub 2008 Mar 6.

PMID:
18323793
4.

Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.

White CL, Menghistu T, Twigger KR, Searle PF, Bhide SA, Vile RG, Melcher AA, Pandha HS, Harrington KJ.

Gene Ther. 2008 Mar;15(6):424-33. Epub 2007 Dec 13.

PMID:
18079753

Supplemental Content

Loading ...
Support Center